CD79A and infection: Manipulation of constituents of saliva, inhibition of viral replication at oral lymphoid sites, or enhancement of anti-viral IgA production may represent novel therapeutic interventions to reduce or eliminate oral FIV infection, as well as the potential to treat HIV-induced oral disease.